Clinical trial NCT03847714: Probiotics in Dementia
Official title: Probiotics in Dementia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dementia; Alzheimer, Mixed Type (Etiology)
Lead sponsor: Medical University of Graz
Sponsor class: OTHER
First posted: 2019-02-20
Enrollment: 17
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Dementia is associated with changes in gut microbiome composition, gut barrier dysfunction, intestinal inflammation and systemic inflammation. Probiotics are a possibility to modulate the gut-brain axis. In this study the effect of probiotics on the gut microbiome and, gut barrier function, inflammation and cognitive dysfunction will be studied.

Detailed description: Dementia is a disease that presents with deterioration in memory, thinking, behaviour and the ability to perform everyday activities. Worldwide 47.5 million people are affected and incidence of dementia is increasing. Dementia leads to disability and dependency among older people worldwide and thereby has a huge physical, psychological, social and economic impact on caregivers, families and society. Alzheimer's disease (AD) is the most common form of dementia accounting for 60-70% of the cases; other forms include Lewy body dementia, frontotemporal dementia, vascular dementia and Parkinson's disease with dementia. In AD, pathologic protein aggregates of amyloid beta and hyperphosphorylated tangles of tau-protein which deposit as neurofibrillary tangles are typical features. This leads to neuroinflammation, mainly mediated by the innate immune system. The most important cells in this process are microglia cells, which represent the resident macrophages of the brain. Although microglia is able to remove extracellular amyloid beta, in later stages of the disease cells remain in a dystrophic state and cannot exert their beneficial functions. Microglia maturation and function is critically dependent on short-chain fatty acids produced by the gut microbiome and therefore highlights the microbiome as a potential diagnostic and therapeutic target in dementia.

The role of the commensal microbial population of the human body - especially the intestinal microbiome - in various diseases is emerging due to the development of advanced analysis techniques. Recently the concept of the gut brain-axis has been established. Several pathways including the autonomic nervous system, the enteric nervous system, the neuroendocrine system and the immune system allow a communication between gut and brain but may also be involved in disease development.

During ageing, the gut microbiome composition undergoes changes. A decrease in diversity, a loss of beneficial taxa and an increase of facultative pathogens has been described. Diet and the place of residence play an important role in the shaping of the microbiome. Aging is also associated with inflammation - often termed as "inflammaging" associated with an increase in gut permeability, mucosal inflammation and bacterial translocation.

Since the main risk factor for developing dementia, especially AD, is aging, it is very likely that the gut-brain axis is critically involved in dementia development.

Animal studies so far suggest that AD is associated with changes in the gut microbiome composition with a decrease in beneficial, anti-inflammatory genera. Furthermore, genetic alterations in amyloid genes can influence microbiome composition in mice, pointing towards a vicious cycle in AD development.

In humans, so far only limited evidence on the microbiome composition in patients with dementia is available. There is evidence that the composition of the microbiome in subgingival plaques is altered in dementia and associated with cognitive function. Recently the first human study identified phylum- through genus-wide differences in bacterial abundance including decreased Firmicutes, increased Bacteroidetes, and decreased Bifidobacterium in the stool of AD patients.

Eligibility criteria: Inclusion Criteria:

* Age \>18 years
* Dementia of Alzheimer type and mixed type (diagnosis by a board-certified neurologist/psychiatrist and according to ICD10)
* Mini Mental State Examination 21-26
* Stable treatment with anti-dementia drugs including phytotherapeutics (\>3 months) or no intention to start anti-dementia drugs
* Informed consent

Exclusion Criteria:

* Other forms of dementia
* Inflammatory bowel diseases
* Liver cirrhosis
* Antibiotic treatment within the last 4 weeks
* Febrile illness within the last 4 weeks
* Acute hospital admission for dementia-unrelated reasons within the last 4 weeks
* Dysphagia
* Any other condition or circumstance, which, in the opinion of the investigator, would affect the patient's ability to participate in the protocol

Primary outcomes:
measure: Butyrate producing bacteria
timeFrame: 6 months
Secondary outcomes:
measure: Butyrate producing bacteria
timeFrame: 12 months
measure: diaminooxidase concentration in serum
timeFrame: 6 months
measure: diaminooxidase concentration in serum
timeFrame: 12 months
measure: zonulin concentration in stool
timeFrame: 6 months
measure: zonulin concentration in stool
timeFrame: 12 months
measure: calprotectin concentration in stool
timeFrame: 6 months
measure: calprotectin concentration in stool
timeFrame: 12 months
measure: soluble CD 14 concentration in serum
timeFrame: 6 months
measure: soluble CD 14 concentration in serum
timeFrame: 12 months
measure: lipopolysaccharide binding protein concentration in serum
timeFrame: 6 months
measure: lipopolysaccharide binding protein concentration in serum
timeFrame: 12 months
measure: lipopolysaccharide concentration in serum
timeFrame: 6 months
measure: lipopolysaccharide concentration in serum
timeFrame: 12 months
measure: peptidoglycan concentration in serum
timeFrame: 6 months
measure: peptidoglycan concentration in serum
timeFrame: 12 months
measure: bacterial DNA concentration in serum
timeFrame: 6 months
measure: bacterial DNA concentration in serum
timeFrame: 12 months
measure: Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS cog)
timeFrame: 6 months
measure: Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS cog)
timeFrame: 12 months
measure: Mini mental state examination
timeFrame: 6 months
measure: Mini mental state examination
timeFrame: 12 months
measure: clinician's interview-based impression of change with caregiver input (CIBIC+)
timeFrame: 6 months
measure: clinician's interview-based impression of change with caregiver input (CIBIC+)
timeFrame: 12 months
measure: Barthel index
timeFrame: 6 months
measure: Barthel index
timeFrame: 12 months
Other outcomes:
Locations:
city: Graz
country: Austria
facility: Medical University Graz
Study officials:
References: